Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Hormonal |
| Evidence grade | A Human trial evidence |
| Regulatory status | FDA-approved |
| Human amounts | FDA labelDosing reference Study durations |
| Format | Lyophilized vial, Liquid spray |
| Type | Single compound |
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1,025.2 g/mol |
| CAS number | Not listed |
| Sequence | Not listed |
| References | 13 |
| Summary | PT-141 is the research name for bremelanotide, a cyclic melanocortin receptor agonist that the FDA approved in 2019 as Vyleesi for a narrowly defined form of low sexual desire in premenopausal women. Its mechanism in HSDD is not known, and its main documented adverse reactions are nausea, flushing, headache, injection site reactions and transient blood pressure changes. This entry summarizes the FDA label, the pivotal trials and the earlier preclinical and male erectile dysfunction studies. |